title: Comment on: "Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting β-Agonists".
authors.affiliation: Boehringer Ingelheim, Asker, Norway.
authors.forename: Carl
authors.initials: C
authors.lastname: Samuelsen
authors.affiliation: Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
authors.forename: Eric D
authors.initials: ED
authors.lastname: Bateman
authors.affiliation: Respiratory Medicine, University of Oxford, Oxford, UK.
authors.forename: Ian
authors.initials: I
authors.lastname: Pavord
authors.affiliation: Health Economics and Outcomes Research, Real-World Evidence Solutions, IMS Health, London, UK.
authors.forename: Adam
authors.initials: A
authors.lastname: Lloyd
authors.affiliation: Boehringer Ingelheim, Ingelheim, Germany.
authors.forename: Mike
authors.initials: M
authors.lastname: Baldwin
authors.affiliation: Boehringer Ingelheim, Ingelheim, Germany. dirk.esser@boehringer-ingelheim.com.
authors.forename: Dirk
authors.initials: D
authors.lastname: Esser
mesh_terms: D000318:Adrenergic beta-Agonists / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000191:economics*; D003362:Cost-Benefit Analysis; D006801:Humans; D012602:Scopolamine Derivatives / Q000191:economics*
chemical_list: D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D012602:Scopolamine Derivatives